WHO ICTRP trial
A multicenter, randomized, double-blind, placebo-controlled study evaluating the…
ChiCTR2600118042 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600118042 |
|---|---|
| Public title | A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of tiotropium bromide N01 injection in the treatment of newly diagnosed patients with thyroid eye disease who have strabismus |
| Scientific title | A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of tiotropium bromide N01 injection in the treatment of newly diagnosed patients with thyroid eye disease who have strabismus |
| Primary sponsor | The Zhongshan Ophthalmic Center,Sun Yat-sen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Thyroid-associated ophthalmopathy |
| Interventions | Control Group:Placebo;Experimental group:Teprotumumab N01 Injection |
| Registration date | Feb 1, 2026 |
| Target size | Control Group:45;Experimental group:45 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: